ReviewF1000Research2023
Monkeypox (mpox) in immunosuppressed patients.
Review in F1000Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Global epidemiology, viral evolution, and public health responses: a systematic review on Mpox (1958-2024).Journal of global health · 2025Pooled it
- Risk factors associated with human Mpox infection: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Discovery and characterization of a hydroxypyridone-3-carboxamide analog as an antiviral lead against orthopoxviruses.Antimicrobial agents and chemotherapy · 2026Article
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- The 2024 Central African Republic monkeypox outbreak: implications for pediatric involvement and global health.Pediatric research · 2026Review
- Decoding Vaccine Hesitancy in Mpox Across Multiple Middle Eastern Countries: Public Knowledge, Attitudes, Worry, Conspiracy Beliefs, and Acceptance.Health science reports · 2026Article
- Summary of the National Advisory Committee on Immunization (NACI) rapid response: Updated guidance on the use of Imvamune® for the prevention of mpox.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Investigating Parental Perception and Intentions Toward COVID-19 Vaccination for Children in Ras Al Khaimah.Health science reports · 2026Article
- Review
- Knowledge and perceptions of monkeypox among university students in Riyadh, Saudi Arabia: implications for public health preparedness.Frontiers in public health · 2026Article
- Discovery and Characterization of a Hydroxypyridone-3-carboxamide Analog as an Antiviral Lead against Orthopoxviruses.bioRxiv : the preprint server for biology · 2025Article
- Severe Anorectal Mpox With Newly Diagnosed HIV and Syphilis: A Diagnostic and Management Challenge.Cureus · 2025Article
- Single-cell sequencing of peripheral blood mononuclear cells reveals immune landscape of monkeypox patients with HIV.Emerging microbes & infections · 2025Article
- Current infectious disease management challenges in inborn errors of immunity.Annals of clinical microbiology and antimicrobials · 2025Review
- Genomic epidemiology of mpox virus during the 2022 outbreak in New York City.Nature communications · 2025Article
- Predictors of mpox infectious periods: findings from a fine and gray sub-distribution hazard model using Vietnamese national mpox data.Epidemiology and infection · 2025Article
- A Severe Form of Mpox Infection and the Current Epidemiological Status in Romania.Microorganisms · 2025Article
- Assessment of healthcare workers' knowledge and attitudes toward mpox and acceptance of its vaccine: a health belief model-based analysis in the Gulf region.Osong public health and research perspectives · 2025Article
- Mpox and cancer: Dual dangers.Medical journal, Armed Forces India · 2025Article
- When public health emergencies hit the front line: a qualitative study of the patient experience in the emergency department and outpatient infectious disease clinic during the 2022 Mpox clade IIb outbreak.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) proclaimed a public health emergency in July 2022 due to the emergence of Mpox (formerly monkeypox) while the globe was still dealing with the COVID-19 epidemic. The characteristics of mpox in immunocompetent individuals are well-characterized, despite difficulties in diagnostics, immunization, and access to treatment that persist in low-income countries. Patients with weakened immune systems are more likely to spread an illness and die from it than healthy people because they cannot mount a protective immune response against it, such as a neutralizing IgG and poxvirus-specific Th1 response. A health warning on severe mpox in people who are immunocompromised due to Human Immunodeficiency virus (HIV) and other illnesses was released by the U.S. Centers for Disease Control and Prevention (CDC) on September 29, 2022. The advice does not specifically include primary immunodeficiency, but it does define other immunocompromising disorders as "having autoimmune disease with immunodeficiency as a clinical component". Both those with healthy immune systems and those with weakened immune systems, such as those who are immunosuppressed, older people, children, etc., have encountered serious health issues, but the latter group is more likely to do so. According to the advisory, "of the people with severe mpox manifestations for whom CDC has been consulted, the majority have had HIV with CD4 counts 200 cells/ml, indicating substantial immunosuppression". However, new cases are still expected to be discovered, especially in low-income countries with limited access to diagnosis, treatment, and prevention, and where a large percentage of the mpox-infected population also has advanced HIV infection. Thus, further research is always needed to determine the best way to treat mpox in immunocompromised people. In this context, we discussed /reviewed the mpox clinical presentation, available treatment options and current preventive guidelines in immunocompromised patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.